Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KEITH H LOVEN

Allopathic & Osteopathic Physicians Dermatology

NPI
1235116518
CMS profile
100500
Location
GOODLETTSVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$3,832.11

94 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $1,920.00 1
Food and Beverage $1,905.15 92
Education $6.96 1

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KEITH H LOVEN

NPI 1235116518 · CMS profile ID 100500

Allopathic & Osteopathic Physicians / Dermatology

GOODLETTSVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1235116518?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KEITH H LOVEN, NPI 1235116518, CMS profile ID 100500. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1235116518?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). KEITH H LOVEN, NPI 1235116518, CMS profile ID 100500. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1235116518?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
KEITH H LOVEN, NPI 1235116518, CMS profile ID 100500, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1235116518?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

94 matching records · $3,832.11 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 94 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–94 of 94.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $23.4406/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795393385 CMS
UCB, Inc. $112.6906/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807361375 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $21.1306/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851899239 CMS
AbbVie Inc. $28.5106/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795393379 CMS
Allergan, Inc. $11.7806/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792857675 CMS
Almirall LLC $18.6306/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819692933 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $19.4805/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851899255 CMS
Janssen Biotech, Inc. $17.2505/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788014973 CMS
Lilly USA, LLC $19.2505/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818631183 CMS
Lilly USA, LLC $20.8105/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818591121 CMS
Novartis Pharmaceuticals Corporation $16.9605/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813038101 CMS
Genentech USA, Inc. $17.4205/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835936185 CMS
AbbVie Inc. $20.5105/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795393375 CMS
Regeneron Healthcare Solutions, Inc. $12.5005/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809600681 CMS
Janssen Biotech, Inc. $18.0005/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788014975 CMS
Sensus Healthcare, Inc. $52.9204/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814080895 CMS
Lilly USA, LLC $15.2904/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818631181 CMS
Amgen Inc. $22.2904/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825505525 CMS
Lilly USA, LLC $22.0304/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818624141 CMS
AbbVie Inc. $25.6304/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795393369 CMS
Novartis Pharmaceuticals Corporation $24.9404/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813038113 CMS
UCB, Inc. $21.6804/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807333963 CMS
AbbVie Inc. $28.7504/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795393363 CMS
Lilly USA, LLC $26.8003/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818647071 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $19.1703/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851899233 CMS
VYNE Pharmaceuticals Inc. $18.9703/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830831157 CMS
Amgen Inc. $19.7803/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825505519 CMS
PFIZER INC. $14.9403/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832524109 CMS
LEO Pharma Inc. $16.3303/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842224931 CMS
AbbVie Inc. $27.2203/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795393357 CMS
Janssen Biotech, Inc. $18.5103/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788014983 CMS
Novartis Pharmaceuticals Corporation $9.6803/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813038109 CMS
AbbVie Inc. $6.9603/04/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795393351 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $22.9602/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851899235 CMS
AbbVie Inc. $27.5102/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795393343 CMS
Amgen Inc. $23.2302/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825505513 CMS
UCB, Inc. $20.0202/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807302899 CMS
Janssen Biotech, Inc. $19.4602/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788014981 CMS
VYNE Pharmaceuticals Inc. $19.8502/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830827057 CMS
Novartis Pharmaceuticals Corporation $20.4202/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813038105 CMS
DERMIRA, INC. $20.4901/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 764403596 CMS
AbbVie Inc. $21.7101/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795393337 CMS
Amgen Inc. $19.1701/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826373853 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $21.1001/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851899237 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $40,883.76 154
PY2020 $10,663.02 95
PY2021 $3,832.11 94
PY2022 $2,018.78 90
PY2023 $6,926.69 110
PY2024 $7,044.88 214
PY2025 $28,488.50 283

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $5,352.41 2
PY2025 Principal investigator $173,111.17 34
PY2024 Principal investigator $6,338.00 2
PY2022 Principal investigator $126.00 1
PY2021 Principal investigator $35,966.70 16
PY2020 Principal investigator $70,753.25 18
PY2019 Principal investigator $121,782.54 41

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

36 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,076.00 12/19/2025 Non-covered Recipient Entity
THE SKIN SURGERY CENTER FOR CL
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223290006
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,290.20 12/18/2025 Non-covered Recipient Entity
Discover Dermatology LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431466
Principal investigator 1 Hoffmann-La Roche Limited $1,830.00 12/01/2025 Non-covered Recipient Entity
Discover Dermatology LLC
VELARITE No dispute reported 06/30/2026 1211597196
Principal investigator 1 Hoffmann-La Roche Limited $2,001.00 12/01/2025 Non-covered Recipient Entity
Discover Dermatology LLC
VELARITE No dispute reported 06/30/2026 1211597202
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,750.32 11/13/2025 Non-covered Recipient Entity
Discover Dermatology LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431460
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,751.56 11/10/2025 Non-covered Recipient Entity
DISCOVER DERMATOLOGY LLC
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup No dispute reported 06/30/2026 1190312965
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $16,250.00 11/07/2025 Non-covered Recipient Entity
Pinnacle Dermatology
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235994589
Principal investigator 1 Hoffmann-La Roche Limited $2,163.00 11/03/2025 Non-covered Recipient Entity
Discover Dermatology LLC
VELARITE No dispute reported 06/30/2026 1211597192
Principal investigator 1 Hoffmann-La Roche Limited $2,618.00 11/03/2025 Non-covered Recipient Entity
Discover Dermatology LLC
VELARITE No dispute reported 06/30/2026 1211597212
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,908.62 10/24/2025 Non-covered Recipient Entity
Discover Dermatology LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431456
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,750.32 10/23/2025 Non-covered Recipient Entity
Discover Dermatology LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431452
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,836.12 10/09/2025 Non-covered Recipient Entity
Discover Dermatology LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431446
Principal investigator 1 Novartis Pharmaceuticals Corporation $216.78 10/08/2025 Non-covered Recipient Entity
GOODLETTSVILLE DERMATOLOGY RESEARCH
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190313173
Principal investigator 1 Hoffmann-La Roche Limited $850.00 10/02/2025 Non-covered Recipient Entity
Discover Dermatology LLC
VELARITE No dispute reported 06/30/2026 1211597172
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 10/01/2025 Non-covered Recipient Entity
THE SKIN SURGERY CENTER FOR CL
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286053
Recipient E.R. Squibb & Sons, L.L.C. $2,400.05 09/23/2025 Covered Recipient Physician Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) No dispute reported 06/30/2026 1236002165
Principal investigator 1 Novartis Pharmaceuticals Corporation $27.00 09/15/2025 Non-covered Recipient Entity
GOODLETTSVILLE DERMATOLOGY RESEARCH
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190306991
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,700.00 09/05/2025 Non-covered Recipient Entity
THE SKIN SURGERY CENTER FOR CLINICAL RESEARCH
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285143
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,750.00 09/05/2025 Non-covered Recipient Entity
THE SKIN SURGERY CENTER FOR CLINICAL RESEARCH
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285145
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,500.00 09/05/2025 Non-covered Recipient Entity
THE SKIN SURGERY CENTER FOR CLINICAL RESEARCH
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285147
Principal investigator 1 Eli Lilly and Company $12,750.00 08/25/2025 Non-covered Recipient Entity
DISCOVER DERMATOLOGY LLC DBA HICKORY DERMATOLOGY RESEARCH CENTER
A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) No dispute reported 06/30/2026 1187878853
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $200.00 08/22/2025 Non-covered Recipient Entity
THE SKIN SURGERY CENTER FOR CLINICAL RESEARCH
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223284549
Principal investigator 1 Novartis Pharmaceuticals Corporation $14,793.50 08/15/2025 Non-covered Recipient Entity
GOODLETTSVILLE DERMATOLOGY RESEARCH
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190313175
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,919.18 08/13/2025 Non-covered Recipient Entity
Discover Dermatology LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431440
Principal investigator 1 PFIZER INC. $1,076.00 08/11/2025 Non-covered Recipient Entity
Discover Dermatology LLC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228714797
Recipient Eli Lilly and Company $2,952.36 07/17/2025 Covered Recipient Physician A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) No dispute reported 06/30/2026 1187871059
Principal investigator 1 Genentech, Inc. $7,500.00 06/20/2025 Non-covered Recipient Entity
Discover Dermatology LLC
VELARITE No dispute reported 06/30/2026 1211597107
Principal investigator 1 Genentech, Inc. $1,550.00 06/20/2025 Non-covered Recipient Entity
Discover Dermatology LLC
VELARITE No dispute reported 06/30/2026 1211597111
Principal investigator 1 Genentech, Inc. $1,750.00 06/20/2025 Non-covered Recipient Entity
Discover Dermatology LLC
VELARITE No dispute reported 06/30/2026 1211597115
Principal investigator 1 Genentech, Inc. $1,750.00 06/20/2025 Non-covered Recipient Entity
Discover Dermatology LLC
VELARITE No dispute reported 06/30/2026 1211597119
Principal investigator 1 Genentech, Inc. $1,750.00 06/20/2025 Non-covered Recipient Entity
Discover Dermatology LLC
VELARITE No dispute reported 06/30/2026 1211597122
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,500.00 06/04/2025 Non-covered Recipient Entity
THE SKIN SURGERY CENTER FOR CLINICAL RESEARCH
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223280674
Principal investigator 1 PFIZER INC. $1,750.00 05/02/2025 Non-covered Recipient Entity
Discover Dermatology LLC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228714719
Principal investigator 1 PFIZER INC. $9,250.00 05/02/2025 Non-covered Recipient Entity
Discover Dermatology LLC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228714721
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $9,000.00 04/24/2025 Non-covered Recipient Entity
Discover Dermatology LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431430
Principal investigator 1 Novartis Pharmaceuticals Corporation $41,203.57 02/01/2025 Non-covered Recipient Entity
DISCOVER DERMATOLOGY LLC
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup No dispute reported 06/30/2026 1190312967